MX2021013888A - Composiciones que comprenden efedrina o una sal de efedrina y metodos de fabricacion y uso de las mismas. - Google Patents

Composiciones que comprenden efedrina o una sal de efedrina y metodos de fabricacion y uso de las mismas.

Info

Publication number
MX2021013888A
MX2021013888A MX2021013888A MX2021013888A MX2021013888A MX 2021013888 A MX2021013888 A MX 2021013888A MX 2021013888 A MX2021013888 A MX 2021013888A MX 2021013888 A MX2021013888 A MX 2021013888A MX 2021013888 A MX2021013888 A MX 2021013888A
Authority
MX
Mexico
Prior art keywords
ephedrine
methods
compositions
manufacturing
salt
Prior art date
Application number
MX2021013888A
Other languages
English (en)
Spanish (es)
Inventor
Shahid Ahmed
Original Assignee
Nexus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73230956&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021013888(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nexus Pharmaceuticals Inc filed Critical Nexus Pharmaceuticals Inc
Publication of MX2021013888A publication Critical patent/MX2021013888A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2021013888A 2019-05-16 2020-05-16 Composiciones que comprenden efedrina o una sal de efedrina y metodos de fabricacion y uso de las mismas. MX2021013888A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962849125P 2019-05-16 2019-05-16
PCT/US2020/033310 WO2020232424A1 (en) 2019-05-16 2020-05-16 Compositions comprising ephedrine or an ephedrine salt and methods of making and using same

Publications (1)

Publication Number Publication Date
MX2021013888A true MX2021013888A (es) 2022-01-24

Family

ID=73230956

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013888A MX2021013888A (es) 2019-05-16 2020-05-16 Composiciones que comprenden efedrina o una sal de efedrina y metodos de fabricacion y uso de las mismas.

Country Status (10)

Country Link
US (7) US11090278B2 (https=)
EP (1) EP3968975A4 (https=)
JP (3) JP2022532657A (https=)
KR (2) KR20240096847A (https=)
CN (1) CN113825500A (https=)
AU (1) AU2020276619A1 (https=)
CA (1) CA3140043A1 (https=)
IL (1) IL288044A (https=)
MX (1) MX2021013888A (https=)
WO (1) WO2020232424A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022532657A (ja) 2019-05-16 2022-07-15 ネクサス ファーマシューティカルズ， インコーポレイテッド エフェドリンまたはエフェドリン塩を含む組成物ならびにその組成物を作製する方法および使用する方法
US10869845B1 (en) 2020-01-22 2020-12-22 Nevakar Inc. Ephedrine compositions and methods
US20230172840A1 (en) * 2021-12-05 2023-06-08 Fresenius Kabi Austria Gmbh Ephedrine liquid formulations
CN120241601B (zh) * 2025-06-04 2025-08-22 成都苑东生物制药股份有限公司 盐酸麻黄碱注射液及其制剂工艺

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK339289D0 (da) 1989-07-07 1989-07-07 Dak Lab As Farmaceutisk praeparat
US7149574B2 (en) * 2003-06-09 2006-12-12 Palo Alto Investors Treatment of conditions through electrical modulation of the autonomic nervous system
FR2890316B1 (fr) 2005-09-02 2007-10-05 Aguettant Soc Par Actions Simp Seringue destinee a etre remplie puis sterilisee par autoclavage a la vapeur.
FR2896168B1 (fr) 2006-01-19 2008-10-17 Aguettant Soc Par Actions Simp Seringue hypodermique preremplie equipee d'un dispositif de bouchage
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
KR101906132B1 (ko) * 2010-07-17 2018-10-10 메르크 파텐트 게엠베하 침투 및 작용의 증진
FR2963237B1 (fr) 2010-07-28 2013-05-17 Aguettant Lab Nouvelle composition pharmaceutique utile pour prevenir ou traiter l'hypotension arterielle peroperatoire chez l'etre humain
CA2828635C (en) * 2011-03-04 2020-01-14 Grunenthal Gmbh Parenteral administration of tapentadol
FR2992222B1 (fr) 2012-06-22 2015-06-19 Aguettant Lab Dispositif de protection destine a equiper un dispositif d’injection pourvu d’un embout de raccordement
US10092701B2 (en) * 2014-05-19 2018-10-09 Medicom Innovation Partner A/S Medical cartridge comprising a one way valve
ES2770731T3 (es) * 2014-08-28 2020-07-02 Sun Pharmaceutical Ind Ltd Forma de dosificación parenteral de norepinefrina
FR3053893B1 (fr) 2016-07-13 2018-07-27 Laboratoire Aguettant Dispositif medical comportant un emballage et une seringue pre-remplie disposee dans l’emballage
CA3051467C (en) * 2017-01-30 2022-11-29 Nevakar, Inc Norepinephrine compositions and methods therefor
WO2019177725A1 (en) 2018-03-13 2019-09-19 Nevakar Inc. Prefilled syringe, compositions and methods
FR3084263B1 (fr) 2018-07-27 2020-07-10 Laboratoire Aguettant Systeme d’administration comportant un dispositif d’administration et un dispositif de protection pourvu d’une membrane de fermeture
JP2022532657A (ja) 2019-05-16 2022-07-15 ネクサス ファーマシューティカルズ， インコーポレイテッド エフェドリンまたはエフェドリン塩を含む組成物ならびにその組成物を作製する方法および使用する方法
US10869845B1 (en) 2020-01-22 2020-12-22 Nevakar Inc. Ephedrine compositions and methods

Also Published As

Publication number Publication date
KR20240096847A (ko) 2024-06-26
US11464752B2 (en) 2022-10-11
US20210353561A1 (en) 2021-11-18
US20210393552A1 (en) 2021-12-23
US11090278B2 (en) 2021-08-17
AU2020276619A1 (en) 2021-12-16
US11241400B2 (en) 2022-02-08
US11478436B2 (en) 2022-10-25
CN113825500A (zh) 2021-12-21
JP2025071269A (ja) 2025-05-02
WO2020232424A1 (en) 2020-11-19
US20200360309A1 (en) 2020-11-19
US20220265580A2 (en) 2022-08-25
US20230068187A1 (en) 2023-03-02
EP3968975A4 (en) 2023-02-15
JP2022532657A (ja) 2022-07-15
KR20220009985A (ko) 2022-01-25
EP3968975A1 (en) 2022-03-23
JP2023091072A (ja) 2023-06-29
US20220257539A1 (en) 2022-08-18
US11426369B2 (en) 2022-08-30
KR102675027B1 (ko) 2024-06-14
US20230025407A1 (en) 2023-01-26
CA3140043A1 (en) 2020-11-19
US20220110892A1 (en) 2022-04-14
US11571398B1 (en) 2023-02-07
IL288044A (en) 2022-01-01

Similar Documents

Publication Publication Date Title
MX2021013888A (es) Composiciones que comprenden efedrina o una sal de efedrina y metodos de fabricacion y uso de las mismas.
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
CL2019003093A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos.
CL2021000909A1 (es) Anticuerpos estabilizadores de trem2
CO2020009625A2 (es) Inhibidor de fap
CL2021000855A1 (es) Replicones basados en alfavirus para la administración de bioterapias.
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
AR114565A1 (es) Proteínas de fusión fc il-22 y métodos de uso
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
AR106025A1 (es) Formas cristalinas de ácido siálico o una sal o solvato de este
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
MX2019015124A (es) Composicion que comprende manosa oligosacarido y proceso para realizarla y uso de esta.
UY36542A (es) Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
AR102203A1 (es) Composiciones para el cuidado oral que comprenden zinc, arginina y serina
CL2023003518A1 (es) Nuevas sales y formas cristalinas de sales de n,n-dimetiltriptamina
UY38841A (es) Composiciones para controlar parásitos
CL2011002675A1 (es) Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende.
CR20160392A (es) Proteínas de fusión tatk-cdkl5, composiciones, formulaciones y uso de esta
MX2019009759A (es) Composiciones de peptido estables.
BR112017014416A2 (pt) sal de mangiferina-6-o-berberina e método de preparação e uso do mesmo
CL2021000580A1 (es) Uso de inhibidores de la caseina quinasa 1 para el tratamiento de enfermedades vasculares.
AR112901A1 (es) Preparación de formas de dosificación sólidas que comprenden anticuerpos por estratificación de solución / suspensión
MX2017011934A (es) Formas solidas de menaquinoles.